Intratumoral microbiota and their emerging role in the tumor microenvironment

Abstract

Intratumoral microbiota, as an important component of the tumor microenvironment, have attracted increasing attention in recent years for their roles in tumor initiation, progression, and therapeutic regulation. Accumulating evidence indicates that low-abundance yet relatively stable microbial communities are present in a variety of solid tumors, exhibiting marked tumor-type specificity and spatial heterogeneity. Current studies suggest that intratumoral microorganisms contribute to tumor progression through multiple mechanisms, including activation of oncogenic signaling pathways, modulation of chronic inflammatory responses, remodeling of the immunosuppressive microenvironment, and regulation of metabolic reprogramming and drug responsiveness. Meanwhile, their bidirectional effects on chemotherapy, radiotherapy, targeted therapy, and immunotherapy highlight their potential roles in determining therapeutic sensitivity and the development of resistance. Despite existing challenges such as low microbial biomass, contamination control, and difficulties in functional validation, advances in spatial multi-omics and single-cell technologies are continuously enhancing the potential clinical value of intratumoral microbiota in tumor diagnosis, prognostic assessment, and precision therapy. This review summarizes the sources, colonization mechanisms, biological functions, roles in therapeutic modulation, and clinical applications of intratumoral microbiota, aiming to provide a theoretical basis for future research and clinical translation.

Keywords

Microorganisms within tumors / tumor microenvironment / immune regulation / treatment response / precision treatment

References

[1] Wroblewski LE,Wilson KT.Helicobacter pylori and gastric cancer: factors that modulate disease risk.Clin Microbiol Rev2010;23:713-39 PMCID:PMC2952980

[2] Salvatori S,Laudisi F,Stolfi C.Helicobacter pylori and gastric cancer: pathogenetic mechanisms.Int J Mol Sci2023;24:2895 PMCID:PMC9917787

[3] Walboomers JMM,Manos MM.Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.J Pathol1999;189:12-9

[4] El-Serag HB.Hepatocellular carcinoma.N Engl J Med2011;365:1118-27

[5] Wu S,Albesiano E.A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses.Nat Med2009;15:1016-22 PMCID:PMC3034219

[6] Kostic AD,Pedamallu CS.Genomic analysis identifies association of Fusobacterium with colorectal carcinoma.Genome Res2012;22:292-8 PMCID:PMC3266036

[7] Castellarin M,Freeman JD.Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma.Genome Res2012;22:299-306 PMCID:PMC3266037

[8] Geller LT,Danino T.Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.Science2017;357:1156-60

[9] Nejman D,Fuks G.The human tumor microbiome is composed of tumor type-specific intracellular bacteria.Science2020;368:973-80 PMCID:PMC7757858

[10] Riquelme E,Zhang L.Tumor microbiome diversity and composition influence pancreatic cancer outcomes.Cell2019;178:795-806.e12 PMCID:PMC7288240

[11] Mai Z,Su J,Yang C.Intra-tumoral sphingobacterium multivorum promotes triple-negative breast cancer progression by suppressing tumor immunosurveillance.Mol Cancer2025;24:6 PMCID:PMC11708301

[12] von Frieling J,Hamm J.Grow with the challenge - microbial effects on epithelial proliferation, carcinogenesis, and cancer therapy.Front Microbiol2018;9:2020 PMCID:PMC6159313

[13] Dong X,He L.The barrier-microbiota-inflammation axis in colorectal cancer: mechanisms and emerging diagnostic & therapeutic strategies.Cancers (Basel)2026;18:576 PMCID:PMC12939124

[14] Tingting Y,Yu Z.Interaction of intratumoral microbiota with the tumor immune microenvironment and its impact on cancer progression.Front Oncol2025;15:1609889 PMCID:PMC12727591

[15] Quagliariello V,Ciappina G.Fusobacteriumnucleatum: pathophysiological and clinical involvement in inflammatory bowel diseases, colorectal cancer and cardiovascular diseases.Cancers (Basel)2025;17:3348

[16] Liao K,Liu Z.The role of intratumoral microbiome in the occurrence, proliferation, metastasis of colorectal cancer and its underlying therapeutic strategies.Ageing Res Rev2025;111:102820

[17] Yin Y,Guo Q.Research and progress on the association of porphyromonas gingivalis with lung cancer.Zhongguo Fei Ai Za Zhi2024;27:799-804.(in Chinese)

[18] Liu Y,Chen K.Clinical significance and prognostic value of Porphyromonas gingivalis infection in lung cancer.Transl Oncol2021;14:100972 PMCID:PMC7718477

[19] Murota Y.Bacteria break barrier to promote metastasis.Cancer Cell2021;39:598-600 PMCID:PMC8982444

[20] Shi Z,Zhang M.Emerging roles of intratumor microbiota in cancer: tumorigenesis and management strategies.J Transl Med2024;22:837 PMCID:PMC11391643

[21] Takahashi M,Nomura S.Impact of tumoral structure and bacterial species on growth and biodistribution of live bacterial therapeutics in xenografted tumours.J Drug Target2023;31:194-205

[22] Luo YC,Wang R.Advancements in understanding tumor-resident bacteria and their application in cancer therapy.Mil Med Res2025;12:38 PMCID:PMC12291306

[23] microbes promote murine breast cancer cell invasion.Cancer Discov2022;12:1407

[24] Fu A,Dong T.Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer.Cell2022;185:1356-1372.e26

[25] Yan D,Liang C.Intratumoral microbiome: the double-edged sword in remodeling cancer immunotherapy.Mol Cancer2026;25:43 PMCID:PMC12934096

[26] Chen F,Li Y.Fusobacterium nucleatum-driven CX3CR1⁺ PD-L1⁺ phagocytes route to tumor tissues and reshape tumor microenvironment.Gut Microbes2025;17:2442037 PMCID:PMC12931713

[27] Schorr L,Elinav E.Intracellular bacteria in cancer-prospects and debates.NPJ Biofilms Microbiomes2023;9:76 PMCID:PMC10562400

[28] Fu A,Dong T.Intracellular microbes empower cancer metastasis.Life Med2022;1:61-3 PMCID:PMC11749340

[29] Bautista J,Adatty-Molina J.Microbial signatures in metastatic cancer.Front Med (Lausanne)2025;12:1654792 PMCID:PMC12518256

[30] Zhang J,Li X,Li J.Harnessing intratumoral microbiota: new horizons in immune microenvironment and immunotherapy.J Transl Med2025;23:897 PMCID:PMC12341252

[31] Shigematsu Y,Amori G.Fusobacterium nucleatum, immune responses, and metastatic organ diversity in colorectal cancer liver metastasis.Cancer Sci2024;115:3248-55 PMCID:PMC11447885

[32] Parhi L,Sol A.Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression.Nat Commun2020;11:3259 PMCID:PMC7320135

[33] McKinley KNL,Riner AN.Translocation of oral microbiota into the pancreatic ductal adenocarcinoma tumor microenvironment.Microorganisms2023;11:1466 PMCID:PMC10305341

[34] Bullman S,Sicinska E.Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.Science2017;358:1443-8 PMCID:PMC5823247

[35] Vayakkattil AB,Andrews S.The Warburg effect redefined: a kinetic and regulatory perspective.Cureus2025;17:e93331 PMCID:PMC12557456

[36] Li J,Liu Y.Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma.Cancer Biol Ther2018;19:1057-64 PMCID:PMC6301813

[37] Lan X,Cui G.Microbiota-directed lactic acid depleting nanoenzyme reactivates antitumor immunity and chemosensitivity in hypoxic tumor.Mater Today Bio2025;35:102493 PMCID:PMC12639497

[38] Situ Y,Zhang C.The metabolic dialogue between intratumoural microbes and cancer: implications for immunotherapy.EBioMedicine2025;115:105708 PMCID:PMC12052696

[39] Cochrane K,Holt RA.A survey of Fusobacterium nucleatum genes modulated by host cell infection.Microb Genom2020;6:e000300 PMCID:PMC7067209

[40] Kwon B.A metabolite of the gut microbiota: a facilitator of chemotherapy efficacy in cancer.Signal Transduct Target Ther2023;8:238 PMCID:PMC10250301

[41] Kong S,Wang L.Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy.Cancer Lett2025;611:217432

[42] Lin P,Chen X,Cui L.Decoding MHC loss: molecular mechanisms and implications for immune resistance in cancer.Clin Transl Med2025;15:e70403 PMCID:PMC12268796

[43] Wang X,Wang Q,Huang Y.Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade.Biochim Biophys Acta Rev Cancer2026;1881:189536

[44] Li H,Liu J.Optimizing mitochondria function in immune cells: implications for cancer immunotherapy.Trends Cancer2025;11:1170-84

[45] Kyriazi AA,Agelaki S.Intratumoral microbiome: foe or friend in reshaping the tumor microenvironment landscape?.Cells2024;13:1279 PMCID:PMC11312414

[46] Noor F.Metabolic causal factor of immune cell function and fate in the tumor microenvironment.Bull Cancer2026;113:777-88

[47] Xu J.Progress on angiogenic and antiangiogenic agents in the tumor microenvironment.Front Oncol2024;14:1491099 PMCID:PMC11611712

[48] Wang R,Zhou J.Crosstalk between anti-angiogenic and pro-angiogenic pathways in disease: mechanisms and therapeutic strategies.Pharmacol Ther2025;276:108934

[49] Peng W,Pu Y.The bidirectional regulatory effects of bacteria on blood vessels in the tumor microenvironment.Discov Oncol2025;16:2011 PMCID:PMC12583279

[50] Liu C,Wang Y.Influence of the gut microbiota on immune cell interactions and cancer treatment.J Transl Med2024;22:939 PMCID:PMC11476117

[51] Bertocchi A,Ravenda PS.Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver.Cancer Cell2021;39:708-724.e11

[52] Gong L,Huang J.Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways.Cancer Biol Med2024;21:1141-55 PMCID:PMC11745089

[53] Abe S,Matsumoto T.Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma.J Gastroenterol2024;59:250-62 PMCID:PMC10904450

[54] Yuan L,Wang Y.Characterization of the landscape of the intratumoral microbiota reveals that Streptococcus anginosus increases the risk of gastric cancer initiation and progression.Cell Discov2024;10:117 PMCID:PMC11589709

[55] Fu K,Wong CC.Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice.Cell2024;187:882-896.e17

[56] Wang Z,Liu Y.Emerging technologies and current challenges in intratumoral microbiota research.Front Cell Infect Microbiol2025;15:1685862 PMCID:PMC12808383

[57] Fu A,Dong T.Emerging roles of intratumor microbiota in cancer metastasis.Trends Cell Biol2023;33:583-93

[58] Harmak Z,Ghouzlani A,Badou A.Beyond tumor borders: intratumoral microbiome effects on tumor behavior and therapeutic responses.Immune Netw2024;24:e40 PMCID:PMC11711125

[59] He X,Shah J,Slupsky CM.Cross-talk between E. coli strains and a human colorectal adenocarcinoma-derived cell line.Sci Rep2013;3:3416 PMCID:PMC3849634

[60] Liu Y,Huang X,Kong C.Characteristic metabolite profile of 10 colorectal cancer-related bacteria.Front Oncol2025;15:1604876 PMCID:PMC12301220

[61] Greathouse KL,Harris CC.Cancer-type-specific bacteria: freeloaders or partners?.Cancer Cell2020;38:158-60

[62] Khan ZA,Ghorbani M.Survival mechanism of pancreatic tumor bacteria and their ability to metabolize chemotherapy drugs.Microbiol Spectr2025;13:e0182025 PMCID:PMC12403566

[63] Kwiatkowska AM,Lafaurie GI,Cardona AF.Exploring the role of the oral microbiome in saliva, sputum, bronchoalveolar fluid, and lung cancer tumor tissue: a systematic review.Transl Oncol2025;62:102557 PMCID:PMC12529560

[64] Zhao F,Ma Y.Integrated spatial multi-omics profiling of Fusobacterium nucleatum in breast cancer unveils its role in tumour microenvironment modulation and cancer progression.Clin Transl Med2025;15:e70273 PMCID:PMC11897063

[65] Li Y,Li X.Hunting field: insights on distribution pattern of bacteria and immune cells in solid tumors.Natl Sci Rev2021;8:nwab023 PMCID:PMC8288350

[66] Hilmi M,Vacher S.Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: an ancillary study of the SHIVA clinical trial.Eur J Cancer2023;183:152-61

[67] Brennan CA.Fusobacterium nucleatum - symbiont, opportunist and oncobacterium.Nat Rev Microbiol2019;17:156-66 PMCID:PMC6589823

[68] Pignatelli P,Piattelli A.The role of Fusobacterium nucleatum in oral and colorectal carcinogenesis.Microorganisms2023;11:2358 PMCID:PMC10537357

[69] Wang P,Zhu Y,Ye K.Fusobacterium nucleatum promotes microsatellite instability in colorectal carcinoma through up-regulation of miRNA-155-5p-targeted inhibition of MSH6 via the TLR4/NF-κB signaling pathway.Adv Biol (Weinh)2024;8:e2400293

[70] Starska-Kowarska K.The role of porphyromonas gingivalis in oral carcinogenesis and progression by remodelling the tumour microenvironment: a narrative review.Cancers (Basel)2025;17:3478 PMCID:PMC12607439

[71] Zeng R,Yu J.New pathogen for gastric cancer: streptococcus anginosus.Clin Transl Med2024;14:e70104 PMCID:PMC11602752

[72] Kowsarkhizi AS,Rahimi A.Targeting Fusobacterium nucleatum in colorectal cancer: therapeutic strategies and future directions.Infect Agent Cancer2025;20:70 PMCID:PMC12522427

[73] Choy ATF,Coppola S.The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine.Expert Rev Mol Diagn2018;18:1005-9

[74] Zhang G.The synthesis of the novel Escherichia coli toxin-colibactin and its mechanisms of tumorigenesis of colorectal cancer.Front Microbiol2024;15:1501973 PMCID:PMC11688353

[75] Taieb F,Nougayrède JP.The enterobacterial genotoxins: cytolethal distending toxin and colibactin.EcoSal Plus2016;7 PMCID:PMC11575708

[76] Saccheri F,Avogadri F.Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity.Sci Transl Med2010;2:44ra57

[77] Li F,Savage TM.Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms.Sci Immunol2024;9:eadn9879 PMCID:PMC11984541

[78] Pushalkar S,Daley D.The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression.Cancer Discov2018;8:403-16

[79] Ochi A,Bedrosian AS.MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells.J Exp Med2012;209:1671-87 PMCID:PMC3428946

[80] Andrade WA,Schmidt T.Group B streptococcus degrades cyclic-di-AMP to modulate STING-dependent type I interferon production.Cell Host Microbe2016;20:49-59 PMCID:PMC5382021

[81] Yu L.Cytosolic DNA sensing by cGAS: regulation, function, and human diseases.Signal Transduct Target Ther2021;6:170 PMCID:PMC8085147

[82] Wang L,Yang M,Liu S.Combination strategies of gut microbiota in cancer therapy through metabolic reprogramming and immune remodeling.Cell Commun Signal2025;23:270 PMCID:PMC12139130

[83] Johnson SA,Wessel HM.Monocytes mediate Salmonella Typhimurium-induced tumor growth inhibition in a mouse melanoma model.Eur J Immunol2021;51:3228-38 PMCID:PMC9214623

[84] Tsuda K,Linan W.Intratumoral injection of Propionibacterium acnes suppresses malignant melanoma by enhancing Th1 immune responses.PLoS One2011;6:e29020 PMCID:PMC3244427

[85] Hajjar R,Santos MM.The role of butyrate in surgical and oncological outcomes in colorectal cancer.Am J Physiol Gastrointest Liver Physiol2021;320:G601-8 PMCID:PMC8238168

[86] Huang X.Microbial imprints on colorectal cancer: the epigenetic silencing of PHLPP1 as a prognostic nexus.BMJ Oncol2025;4:e000883 PMCID:PMC12320035

[87] Eaton SE,Mahmood D.Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients.Br J Cancer2022;127:2087-98 PMCID:PMC9727022

[88] Gur C,Isaacson B.Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.Immunity2015;42:344-55 PMCID:PMC4361732

[89] Yu T,Yu Y.Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy.Cell2017;170:548-563.e16 PMCID:PMC5767127

[90] Shi Y,Yang K.Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling.J Exp Med2020;217 PMCID:PMC7201921

[91] Han ZY,Wang YZ.Probiotics functionalized with a gallium-polyphenol network modulate the intratumor microbiota and promote anti-tumor immune responses in pancreatic cancer.Nat Commun2024;15:7096 PMCID:PMC11330462

[92] Zheng SH,Feng G.Gut microbiota reshaping the pancreatic cancer immune microenvironment: new avenues for immunotherapy.Mol Cancer2025;24:313 PMCID:PMC12755029

[93] Yang L,Wang Y.Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy.Signal Transduct Target Ther2023;8:35 PMCID:PMC9842669

[94] Shalapour S.Cruel to be kind: epithelial, microbial, and immune cell interactions in gastrointestinal cancers.Annu Rev Immunol2020;38:649-71 PMCID:PMC8936002

[95] Silver NL,Kerr TD.Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma.Nat Cancer2026;7:80-97 PMCID:PMC12823012

[96] Vella G.Cancer microbiota: a focus on tumor-resident bacteria.EMBO Rep2025;26:2977-93 PMCID:PMC12187936

[97] Rubinstein MR,Lagana SM.Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1.EMBO Rep2019;20:e47638 PMCID:PMC6446206

[98] Zhou X,Shen Z.Eliminating intratumoral bacteria with cGAS-STING-activating nanodrug-bacteria biohybrids potentiates cancer immunotherapy.Biomaterials2026;325:123629

[99] Arjunan P,Pi W.Oral pathobiont activates anti-apoptotic pathway, promoting both immune suppression and oncogenic cell proliferation.Sci Rep2018;8:16607 PMCID:PMC6226501

[100] Lin X,Chen P.Regulatory mechanisms of PD-1/PD-L1 in cancers.Mol Cancer2024;23:108 PMCID:PMC11102195

[101] Chen J,Ye X,Wang K.Gut microbiota-mediated activation of GSDMD ignites colorectal tumorigenesis.Cancer Gene Ther2024;31:1007-17 PMCID:PMC11257976

[102] Malvankar S,Bhat PP.Regulation of cancer by inflammasomes: from inflammation to tumorigenesis.Front Immunol2025;16:1611719 PMCID:PMC12277140

[103] Grivennikov SI.Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer.Cytokine Growth Factor Rev2010;21:11-9 PMCID:PMC2834864

[104] He G.NF-κB and STAT3 - key players in liver inflammation and cancer.Cell Res2011;21:159-68 PMCID:PMC3193410

[105] Senthil Kumar S,Reinartz DM.Oral streptococci S. anginosus and S. mitis induce distinct morphological, inflammatory, and metabolic signatures in macrophages.Infect Immun2024;92:e0053623 PMCID:PMC10929413

[106] Rubinstein MR,Liu W,Cai G.Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin.Cell Host Microbe2013;14:195-206 PMCID:PMC3770529

[107] Yang Y,Peng J.Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of MicroRNA-21.Gastroenterology2017;152:851-866.e24 PMCID:PMC5555435

[108] Li L,Liao B.Orally administrated hydrogel harnessing intratumoral microbiome and microbiota-related immune responses for potentiated colorectal cancer treatment.Research (Wash D C)2024;7:0364 PMCID:PMC11077293

[109] Sadeghloo Z,Hakemi-Vala M,Sadeghi A.Fusobacterium nucleatum and non-coding RNAs: orchestrating oncogenic pathways in colorectal cancer.Gut Pathog2025;17:78 PMCID:PMC12495833

[110] He S,Qi C.Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy.Mol Cancer2025;24:5 PMCID:PMC11707952

[111] Zou Y,Liu F,Tang H.Intratumoral microbiota in orchestrating cancer immunotherapy response.J Transl Int Med2024;12:540-2 PMCID:PMC11720933

[112] Guo J,Li J.Fusobacterium nucleatum promotes PD-L1 expression in cancer cells to evade CD8⁺ T cell killing in breast cancer.Hum Immunol2024;85:111168

[113] Erturk-Hasdemir D,Okan NA.Symbionts exploit complex signaling to educate the immune system.Proc Natl Acad Sci U S A2019;116:26157-66 PMCID:PMC6936714

[114] Luu M,Wedi F.Regulation of the effector function of CD8⁺ T cells by gut microbiota-derived metabolite butyrate.Sci Rep2018;8:14430 PMCID:PMC6158259

[115] Lu Q,Yu X,Song Z.Unveiling the interplay between microbiota and PD1/PD-L1 axis in tumor immunity and immunotherapy.Front Immunol2025;16:1690374 PMCID:PMC12695803

[116] Tan Q,Zou F,Xiong L.Spatial heterogeneity of intratumoral microbiota: a new frontier in cancer immunotherapy resistance.Biomedicines2025;13:1261 PMCID:PMC12108975

[117] Kalaora S,Nejman D.Identification of bacteria-derived HLA-bound peptides in melanoma.Nature2021;592:138-43

[118] Chen J,Kroemer G,Zitvogel L.The microbiota in radiotherapy-induced cancer immunosurveillance.Nat Rev Clin Oncol2025;22:667-79

[119] Benej M,Kreamer M.exORIEN ConsortiumThe tumor microbiome reacts to hypoxia and can influence response to radiation treatment in colorectal cancer.Cancer Res Commun2024;4:1690-701 PMCID:PMC11234499

[120] Dolmans DE,Jain RK.Photodynamic therapy for cancer.Nat Rev Cancer2003;3:380-7

[121] Kong F,Zhang Y.Abundance and metabolism disruptions of intratumoral microbiota by chemical and physical actions unfreeze tumor treatment resistance.Adv Sci (Weinh)2022;9:e2105523 PMCID:PMC8895135

[122] Diop K,Nili S.Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors.Gut Pathog2025;17:21 PMCID:PMC11992761

[123] He X,Zhang J.Potential and application of Fusobacterium nucleatum in the diagnosis and treatment of colorectal cancer.Front Microbiol2025;16:1652702 PMCID:PMC12518349

[124] Asgharzadeh S,Bahador A.The microbial landscape of tumors: a deep dive into intratumoral microbiota.Front Microbiol2025;16:1542142 PMCID:PMC12129932

[125] Feigenberg SJ,Tanes C.Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study.J Immunother Cancer2025;13:e011356 PMCID:PMC12258320

[126] Singh S,Baek KR.Anti-cancer strategies using anaerobic spore-forming bacteria clostridium: advances and synergistic approaches.Life (Basel)2025;15:465 PMCID:PMC11943571

[127] Chen H,Yang C.Distinctive circulating microbial metagenomic signatures in the plasma of patients with lung cancer and their potential value as molecular biomarkers.J Transl Med2025;23:186 PMCID:PMC11829562